Age-related macular degeneration (AMD) is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving.

AMD affects the macula, the part of the eye that allows you to see fine detail. AMD causes no pain.

In some cases, AMD advances so slowly that people notice little change in their vision. In others, the disease progresses faster and may lead to a loss of vision in both eyes. AMD is a leading cause of vision loss in Americans 60 years of age and older.

Resolution/Product The very inexpensive, MDD-1TM Macular Defective Detection Device‟ developed and produced by Health Research Sciences, Inc. (HRS) enables Optometrist, Ophthalmologist, Endocrinologist, Primary Care Doctors, and even patients themselves in the home environment to easily and efficiently screen for the early detection of Age Related Macular Degeneration and Diabetic Maculopathy as well as other types of central retinal diseases in the human eye. The MDD-1 also permits monitoring of central retinal health over time, and can warn of deterioration in function at an early stage.

The MDD-1 is a Patented, unique design that solves the problem of inconsistent testing and screening as currently performed by providing reproducible measurements of macular function (light flash recovery, dark adaptation) that are recorded and made available in a concise reporting format for health professional interpretation. The instrument also warns end users that a doctor‟s visit is warranted.

It is envisioned that the MDD-1 would be sold directly to these Physicians in enough quantity per office to facilitate the screening of patients that fit the target patient demographic in their normal busy weekly schedules.

HRS will develop the educational and marketing material required to supply the physicians with what is needed to inform and educate their patient populations about the presence of the MDD-1 in their office and the need and ability to have screening and monitoring performed on patients that are in the risk demographic. The educational material developed for this purpose by HRS will contain the statistical information about the screened and monitored diseases and the need to be screened.

It is estimated that the total reduction in cost of care is significant as many large Eye Health Organizations in the US have already evaluated the MDD-1 and concluded and reported to HRS that “early detection and standardization of the test parameters and baselines is what is needed to screen these diseases at an early stage which would allow the initiation or augmentation of inexpensive initial therapies (including the use of Nutriceuticles), or more involved treatments (laser, anti-VEGF injections) as may be indicated for more advanced disease.

Conclusion The MDD-1 Macular Defective Detection Device is the only testing and screening device of its type in the world and the same “large Eye Health Organizations in the US” that have initially reviewed the MDD-1 have stated that they believe that “every Doctor they know needs to have one to raise the standard of care for screening for these diseases and monitoring the success of applied therapies and corrective surgery”.